Published: Tue, May 09, 2017
Markets | By Erika Turner

Horizon Pharma PLC (NASDAQ:HZNP) To Buy River Vision Development


The relative volume (ratio between current volume and 3-month average) is presently sitting at 1.09.

On 3/1/2017 Robert Carey, EVP, sold 31,808 with an average share price of $16.03 per share and the total transaction amounting to $509,882.24. Thanks to an increase of nearly 9.8% in the past one month, the stock price is now with underperforming -3.71% so far on the year - still in weak zone. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Profund Advisors LLC increased its position in shares of Horizon Pharma PLC by 0.8% in the first quarter. The Beach Point Capital Management Lp holds 213,544 shares with $3.46M value, down from 1.16 million last quarter.

Hodges Capital Management Inc increased Horizon Pharma Plc (HZNP) stake by 4.35% reported in 2016Q4 SEC filing. Overall, the company has an average negative earnings surprise of 11.56%. It turned negative, as 40 investors sold Horizon Pharma PLC shares while 69 reduced holdings. Its last 5-Year EPS growth stands at 39.30% with earnings growth of -645.10% yoy. Mizuho maintained Horizon Pharma PLC (NASDAQ:HZNP) on Tuesday, November 10 with "Buy" rating. For the past 5 days of trading, the stock has seen a move of 1.30%.

A number of institutional investors have recently made changes to their positions in HZNP. JMP Securities reinitiated the shares of HZNP in report on Wednesday, September 9 with "Mkt Outperform" rating. Mizuho reissued a "buy" rating and set a $25.00 price target on shares of Horizon Pharma PLC in a research note on Wednesday, February 22nd. Piper Jaffray Companies dropped their price target on Horizon Pharma PLC from $32.00 to $30.00 and set an "overweight" rating for the company in a report on Friday, March 24th. Horizon Pharma had 24 analyst reports since September 9, 2015 according to SRatingsIntel. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. They now have a Dollars 24 price target on the stock. About 31,831 shares traded. Jpmorgan Chase invested 0.03% in Horizon Pharma PLC (NASDAQ:HZNP). The stock closing price is now trading downward to its 50 day moving average with change of -0.10%, escalated to its 20 day moving average with figure of 0.64% and behind its 200 day moving average with value -13.44%.

Army arrests 12-year-old PoK boy along LoC in J&K
Pakistan on Sunday claimed that its four civilians were injured in cross-LoC firing by Indian forces. On being challenged by the army's patrol party, the boy immediately surrendered, the spokesman said.

Horizon Pharmaceuticals (HZNP) is getting killed today, losing more than one third of its value and hitting a 52-week low after the drug maker's first quarter financial results and its full-year sales forecasts all missed expectations. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.51 by $0.13. Fincl Services has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP).

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted collaboration revenues of approximately $10.5 million, compared to our consensus estimate of $10 million.

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. If you are accessing this story on another publication, it was illegally copied and reposted in violation of USA and worldwide trademark & copyright law.

Just seven months after Horizon Pharma's $800 million Raptor rare disease buy, the Irish biotech is spending $145 million, plus biobucks, for River Vision and its inflammatory eye drug teprotumumab.

Like this: